Insmed Incorporated (NASDAQ:INSM) announced today the Department of Defense has granted a group of leading oncologists $10 million to support therapeutic individualization for breast cancer treatment in a translational research project. Insmed’s rhIGFBP-3 has been selected as one of the candidate therapies for study. The lead investigator for the trials with rhIGFBP-3 is Dr. Brian Leyland-Jones of McGill University, former Head of Developmental Chemotherapy at the National Cancer Institute. The consortium of physicians collectively called the Breast Cancer Center of Excellence will use the emerging technologies of genomics, proteomics, and pharmacogenetics to predict individual response to therapeutic agents in advanced breast cancer. The desired outcome of the study will be to maximize patient benefit while minimizing the toxic side effects of standard therapies on the market today.
